. Schematic representation of steps in the original hypothesis for processing and presentation of glycoconjugate vaccine epitopes and consequent CD4+ helper T-cell induction of B-cell production of IgG antibodies to the polysaccharide. 
. Schematic representation of steps in the original hypothesis for processing and presentation of glycoconjugate vaccine epitopes and consequent CD4+ helper T-cell induction of B-cell production of IgG antibodies to the polysaccharide. (1) Polysaccharide-protein conjugates bind to the B-cell receptor (BCR) of polysaccharide-specific pre-B cells. (2) Conjugates are taken up into the endosome of B cells. (3) Once a conjugate is inside a cell, the protein portion is digested in the endolysosome by acid proteases to release peptides. (4) Peptides bind to MHCII molecules with the help of HLA-DM to replace the CLIP portion of the self-peptide. (5) The peptide from the vaccine carrier protein in the context of MHCII is presented to the CD4+ T cell (αβTCR). (6) Along with co-stimulatory molecules, peptide/MHCII activates the αβTCR. (7) Cytokines like IL-4 and IL-2 are secreted by the CD4+ T cell. The cognate interactions of the B cell with the T cell, in combination with the action of cytokines, stimulate B-cell maturation and induce both immunoglobulin class switching (from IgM to polysaccharide-specific IgG) and B-cell memory. Figure S3 . Chemistry for radiolabeling of GBSIII followed by conjugation to carrier protein/peptide. In brief, GBSIII has a side-chain sialic acid residue on each repeating unit. A selected number of these sialic acids can be oxidized with sodium periodate to create an aldehyde at C7 or C8. Radioactive labeling takes place by reduction of the aldehyde with [3H]sodium borohydride. A selected additional number of the nontritiated sialic acids can then be oxidized, and the aldehyde that is formed can be linked as a secondary amine to lysine groups in the protein by means of reductive amination.
Supplementary Figure 4

Endolysosomes
Cell Surface Figure S4 . Fractionation of Raji B cells by differential centrifugation yielded endolysosomes and cell surface fractions. Western blot analysis of the solubilized endolysosomes showed endosomal (Rab5) and lysosomal (LAMP-1) proteins, and cell surface fractions contained membrane proteins (CD19). None of the isotype controls for the antibodies used in the assay labeled proteins in the membranes (not shown). Serial dilutions of endolysosomal content were run on the gels along with undiluted cell-surface fraction. After transfer and labeling of the membranes, both fractions were exposed to films simultaneously until bands for LAMP-1 and Rab5 were observed on the cell surface fractions. These bands on the cell surface fractions had the same density as 25X-diluted LAMP-1 and Rab5 bands from endolysosomal fractions. This result demonstrated that the cell surface fraction was 95% free of endosomes and lysosomes (not shown). ) and Superose 12 molecular sizing column analysis of cell surface content immunoprecipitated with mAb to HLA-DR revealed that low-molecular-weight GBSIII (~10 kDa) was bound to MHCII molecules at the Raji cell surface. As a negative control, this experiment was repeated with MHCII-deficient Raji cells (RJ2.2.5), and no tritiated oligosaccharide was detected at the cell surface (pink). As a control for the mAb to MHCII used for co-IP, an antibody to LAMP-1 was used; no counts were detected in this immunoprecipitate (not shown). Figure S7 . Characterization of a cell surface complex containing MHCII, OVAp, or GBSIII. Cell membrane extracts of Raji B cells incubated with III-OVAp or GBSIII (a) and with OVAp or GBSIII (b) were run on SDS gels and stained by western blotting with antibodies to HLA-DR, OVAp, and GBSIII. A band at ~82 kDa was detected by all three antibodies in the III-OVAp-incubated cell membrane extracts, a result suggesting that a complex of MHCII and a glycanp-peptide exists on the surface of these B cells. As control antibodies, a mouse IgG2a isotype (a control for HLA-DR and GBSIII antibodies) or normal mouse serum (a control for OVAp antibodies) were used in both a and b. None of the PVDF membranes showed a band when incubated with control antibodies (data not shown). Raji cells were incubated with a control non-HLA-binding peptide (i.e., scrambled OVAp) and the PVDF membrane didn't show a band after labeling with antibody to OVAp. . III-OVA has a bulky matrix-like structure with one or two antigenic glycanp-peptides per polysaccharide chain (with an assumption that the peptide portion of each glycan p -peptide is an MHCII-binding peptide). III-OVAp has a uniform structure containing ~8 glycanp-peptide epitopes per carbohydrate chain based on the carbohydrate-to-peptide mass ratios in the conjugate (3:1). The single-chain presentation of III-OVAp is based on the coupling chemistry. OVAp can react with only one aldehyde group on the sugar chain through its free amino group at the C-terminus lysine residue; the N-terminus is N-acetylated.
